Primary membranous glomerulonephritis | UniteRare Disease Library

Overview

Also known as:

Primary membranous nephropathy Idiopathic membranous glomerulonephritis

Clinical phenotype terms:

Anti-phospholipase A2 receptor antibody positivityHP:0034002

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events

Oct 2026A Phase I Study of YK012 in Primary Membranous Nephropathy

Excyte Biopharma Ltd — PHASE1

TrialNOT YET RECRUITING

Feb 2026Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

The First Affiliated Hospital of Zhejiang Chinese Medical University — EARLY_PHASE1

TrialNOT YET RECRUITING

Dec 2025Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE2

TrialRECRUITING

Sep 2025A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Vertex Pharmaceuticals Incorporated — PHASE2, PHASE3

TrialRECRUITING

Sep 2025Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Alexion Pharmaceuticals, Inc. — PHASE2

TrialRECRUITING

Aug 2025A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Climb Bio, Inc. — PHASE2

TrialRECRUITING

Jun 2025A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Shanghai JMT-Bio Inc. — PHASE2

TrialNOT YET RECRUITING

May 2025A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Biogen — PHASE3

TrialRECRUITING

Mar 2025Study of YK012 in Primary Membranous Nephropathy

Excyte Biopharma Ltd — PHASE1

TrialRECRUITING

Nov 2024An Outcome Analysis of Primary Membranous Nephropathy

Mario Negri Institute for Pharmacological Research

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Primary membranous glomerulonephritis.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →

Phase 35 trials

OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)

Phase 3

Actively Recruiting

· Sites: Shanghai, Shanghai Municipality · Age: 18–75 yrs

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Phase 3

Active

PI: Clinical Trials (Hoffmann-La Roche) · Sites: San Francisco, California; Aurora, Colorado +48 more · Age: 18–75 yrs

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Phase 3

Actively Recruiting

PI: Medical Director (Biogen) · Sites: Huntsville, Alabama; Fresno, California +76 more · Age: 18–80 yrs

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

Phase 3

Active

· Sites: Beijing · Age: 18–80 yrs

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Phase 3

Actively Recruiting

· Sites: Los Angeles, California; San Dimas, California +29 more · Age: 18–99 yrs

Phase 41 trial

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Phase 4

Actively Recruiting

· Sites: Guangzhou, Guangdong · Age: 18–75 yrs

Phase 26 trials

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

Phase 2

Active

· Sites: Shanghai, Shanghai Municipality · Age: 18–75 yrs

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Phase 2

Actively Recruiting

· Sites: Loma Linda, California; San Diego, California +37 more · Age: 18–75 yrs

Belimumab With Rituximab for Primary Membranous Nephropathy

Phase 2

Actively Recruiting

PI: Patrick Nachman (University of Minnesota, Department of Medicine, D) · Sites: Birmingham, Alabama; Little Rock, Arkansas +18 more · Age: 18–75 yrs

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Phase 2

Actively Recruiting

· Sites: Nanjing, Jiangsu · Age: 18–75 yrs

Obinutuzumab in Primary MN

Phase 2

Active

· Sites: Bergamo, BG; Ranica, BG · Age: 18–99 yrs

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Phase 2

Actively Recruiting

· Sites: Denver, Colorado; Orlando, Florida +31 more · Age: 18–70 yrs

Phase 12 trials

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Phase 1

Actively Recruiting

· Sites: Zhengzhou, He'nan; Shijiazhuang, Hebei +4 more · Age: 18–75 yrs

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Phase 1

Actively Recruiting

· Sites: Changsha, Changsha; Chongqing, Chongqing Municipality +17 more · Age: 18–75 yrs

Other3 trials

A Real World Study About PMN

Actively Recruiting

· Sites: Guangzhou, Guangdong · Age: 18–99 yrs

An Outcome Analysis of Primary Membranous Nephropathy

Actively Recruiting

PI: Giuseppe Remuzzi, MD (Istituto Di Ricerche Farmacologiche Mario Negri) · Sites: Bergamo, BG; Ranica, BG · Age: 18–99 yrs

Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study

Active

PI: Yipeng Liu (Qianfoshan Hospital) · Sites: Jinan, Shandong

Specialists

Showing 25 of 45View all specialists →

GM

GALEANO CRISTINA, MD

Specialist

PI on 1 active trial

Overview

FDA & Trial Timeline

Treatments

Clinical Trials

Specialists

Treatment Centers

Travel Grants

Community

Latest news about Primary membranous glomerulonephritis

Caregiver Resources

Common questions about Primary membranous glomerulonephritis